Low-Dose Rituximab Safe, as Effective as High Dose in MS

September 24, 2020

By Marco Meglio

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.